Medical/Pharmaceuticals
IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
* IMU's AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time. * Waters Biosciences' technologies, including BD FACSDiscover™ and BD Rhapsody™ Instruments, will be used with IMU's AI analy...
2026-06-24 20:00
3826
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Team (ELT) effective 1 September 2026. Tarek Samad succeeds Johan ...
2026-06-24 18:19
4278
World's First Solid Tumor CAR-T Approved: Jiahui International Cancer Center Provides Access for Patients Worldwide
SHANGHAI, June 24, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) welcomes the approval of Satri-cel (CT041, Kaileimei®), the world's first CAR-T cell therapy approved for the treatment of a solid tumor, marking a historic milestone in cancer care and opening new possibilities for...
2026-06-24 17:01
3492
Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
* Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart * Eptinezumab data explore patient-centered outcomes in chronic migra...
2026-06-24 16:08
3067
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules
SHANGHAI, June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Everest Medicines and Hainan He...
2026-06-24 15:07
4821
Milliken Expands Innovation Capabilities with New Polymer Solutions Pilot Plant in Pune, India
Facility strengthens ability to accelerate development and scale advanced materialsolutions for global markets. PUNE, India, June 24, 2026 /PRNewswire/ -- Milliken & Company has opened a new state of the art pilot plant facility in Pune, India, further strengthening its polymer solutions busine...
2026-06-24 14:24
3537
Cynosure Lutronic Spotlighted Structural Skin Tightening Innovation at IMCAS Asia 2026 in Bangkok
SINGAPORE, June 24, 2026 /PRNewswire/ -- Global medical aesthetics leader Cynosure Lutronic presented its latest non-invasive innovations at IMCAS Asia 2026 in Bangkok (19–21 June), featuring XERF™, a structural skin tightening treatment that focuses on comfort, safety, flexibility and no downtim...
2026-06-24 13:14
4216
Great Place To Work Reveals Southeast Asia's Best Workplaces™ in Healthcare & Biopharma
SINGAPORE, June 24, 2026 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, today announced the inaugural Southeast Asia's Best Workplaces™ in Healthcare & Biopharma 2026 list — a landmark recognition honouring 15 outstanding organizations that have set the benchmark...
2026-06-24 12:18
4340
Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026
SHENZHEN, China, June 24, 2026 /PRNewswire/ -- From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhib...
2026-06-24 11:53
2775
Abu Dhabi Opens Strategic Life Sciences Corridor to California Through Biocom Partnership
ABU DHABI, UAE, June 24, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Biocom California, one of the world's largest life sciences associations representing more than 1,800 biotechnology, pharmaceutical and medical techno...
2026-06-24 07:11
3720
EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services
PROVIDENCE, R.I., June 23, 2026 /PRNewswire/ -- EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded space has more than doubled the company's laboratory footprint, expanding the ...
2026-06-23 21:12
2748
Ambulatory Surgical Centres Poised for Sustained Growth as Healthcare Delivery Continues to Shift Beyond the Hospital
Frost & Sullivan identifies significant opportunities across ambulatory surgery, digital health, and connected care markets LONDON, June 23, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis highlights ambulatory surgical centres (ASCs) as one of the most significant growth opportunities r...
2026-06-23 20:17
2892
Fair Play Menarini International Award
Diego Milito and Emilio Butragueño among the winners of the 30th edition FLORENCE, Italy, June 23, 2026 /PRNewswire/ -- The list of winners of the 30th Fair Play Menarini International Award, scheduled forJuly 2 in Florence, continues to include great legends of world sport. Among the champions w...
2026-06-23 18:29
1963
Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
* Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug ...
2026-06-23 18:10
4199
CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
SEOUL, South Korea, June 23, 2026 /PRNewswire/ -- Informa Markets Korea has
officially opened pre-registration for CPHI/ Hi Korea 2026, taking place at
COEX, Seoul, from August 25 to 27. Pre-registered visitors enjoy complimentary
entries.
2026-06-23 08:00
5265
DoH and Sanofi Partner to Advance Vaccine Innovation
ABU DHABI, UAE, June 23, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines leader, have signed an Memorandum of Understanding and intend to into an agreement to advance their partner...
2026-06-23 07:47
5893
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address ...
2026-06-23 05:37
6090
Texas A&M Study Highlights Pictor PictVet® as a Promising New Tool for Non-Invasive Beef Cattle Health Monitoring
Independent peer-reviewed research published in Frontiers in Veterinary Science reports strong assay performance in a proof-of-concept evaluation using bovine nasopharyngeal swab samples CARLSBAD, Calif., June 23, 2026 /PRNewswire/ -- Pictor Holdings Inc., a global targeted proteomic platform co...
2026-06-23 01:37
3336
Biomerics Appoints Kristin Mason as Chief Financial Officer
SALT LAKE CITY, June 22, 2026 /PRNewswire/ -- Biomerics, a leading vertically integrated contract manufacturer for the interventional medical device market, today announced the appointment of Kristin Mason as Chief Financial Officer. Mason joins Biomerics following an extensive career leading fin...
2026-06-22 22:03
3374
Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
* European approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and progression-free sur...
2026-06-22 21:14
3639
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
[Picked up by 292 media titles]
2026-07-30 09:12
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
[Picked up by 291 media titles]
2026-07-27 19:02
ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
6887
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
2026-07-27 19:02
5970
KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
2026-07-30 09:12
5597